Basel, July 2, 2026 – Novartis today announced that the European Commission (EC) has approved Itvisma ® (onasemnogene ...

About Novartis Immunology At Novartis, we’re advancing bold science for autoimmune diseases, where meaningful therapeutic progress has long stalled. With a growing legacy of first-in-class innovation ...

The need to improve access to medicines remains one of the world’s greatest healthcare challenges. Through the Novartis Access Principles, we are committed to expanding access to our medicines to ...

Our work is powered by a toolkit of five R&D approaches – two established platforms (chemistry and biotherapeutics) plus three advanced platforms (xRNA, radioligand therapy and gene and cell therapy) ...

In an era when global health challenges are greater than ever, and where medical science is advancing at an unprecedented rate, we have the opportunity to make a real difference for patients and ...

With new tools and approaches comes broader opportunity to benefit patients. Cardiovascular and metabolic diseases are responsible for nearly 18 million deaths worldwide each year and represent a huge ...

Animal research is key to many of the great medical advances of today, including cancer treatments; medicines to treat neurological diseases such as multiple sclerosis, medicines for diseases that ...

Transforming the treatment and healthcare system landscape using early interventions, pioneering treatments, and innovative partnerships to avoid preventable mortality from cardiovascular disease (CVD ...

Continuously rising dividend since 1996 Shareholders approved the 29th consecutive dividend increase per share since the creation of Novartis in 1996, with an increase of 5.7% to CHF 3.70 per share ...

Our purpose at Novartis is to reimagine medicine to extend and improve people’s lives. To reflect this, we embrace pioneering collaborations and partner with external scientific experts to mutually ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Disclaimer: The information provided on this website does not constitute investment advice, or an offer of, or an invitation or solicitation by, or on behalf of, Novartis AG or any of its subsidiaries ...